Washington, DC (PRWEB) February 21, 2014
MDLinx.com, part of the M3 Group, and the number one physician specialty website in the US, with the largest single site for healthcare professionals in the EU and the Nordics, breaks new ground with the introduction of their international physician verification program.
“Most physician websites are built in one language, for one country and verify physicians country by country in verification silos, with no global standards evident,” comments Craig Overpeck, CTO of MDLinx and COO of M3 Global Research. “Our new international verification program is an M3 First, reaching out globally to all physicians who use our MDLinx platform, engaging them in their language and credentialing with diplomas or licenses. The ultimate goal is to insure we have the most verified physician panel for opt-in market research and to communicate our pharma content directly to the intended subscribed physician audience… out of the reach of non-physicians."
This new international verification program is indicative of the M3 Group corporate DNA that values the relentless pursuit of accuracy and credibility for their physician members and their valued, expanding global client base.
“We have been verifying physicians for years in the US, G5, Japan, Russia, Korea, and China,” adds Mr. Overpeck. “As we move into more countries where there is not a central database of physicians, we saw the need to clearly show which physicians are verified and which are not. That’s why this verification initiative is integral to our continued global expansion.”
Recently MDLinx.com was named “Best Healthcare Professional Media Brand” by the prestigious trade publication Medical Marketing and Media.
About M3 Group
The M3 Group operates in the US, Asia, and Europe with over 2.5 million physician members globally via its physician websites such as http://www.m3.com, http://www.mdlinx.com, http://research.m3.com, http://www.doctors.net.uk, http://www.medigate.net and http://www.medlive.cn. M3 Inc. is a publicly traded company on the Tokyo Stock Exchange (jp:2413) with subsidiaries in major markets including USA, UK, Japan, S. Korea, and China. M3 Group provides services to healthcare and the life science industry. In addition to market research, these services include medical education, ethical drug promotion, clinical development, job recruitment, and clinic appointment services. M3 has offices in Tokyo, Washington D.C., Fort Washington, PA, Oxford, London, and Seoul.
M3 Group Sites: